Isis Pharmaceuticals, GlaxoSmithKline deal

Isis said it amended a 2010 deal with GlaxoSmithKline and now will receive $2.5 million upfront and is eligible to receive a $7.5 million milestone payment triggered by the start of a Phase II/III trial of ISIS-TTRRx to treat familial amyloid polyneuropathy (FAP). Isis expects to start the trial later this year. Isis is also eligible to receive up to $50 million in pre-licensing milestones to support the trial. Additionally, GSK increased the regulatory and sales milestones payable to Isis for the program, but Isis said the amount is undisclosed. The amended deal accounts for the use of a pivotal Phase II/III trial, while the payments under the original deal accounted for separate Phase II and Phase III trials. ...